BioArctic hires Anders Martin-Löf as new CFO

Rhea-AI Summary

BioArctic AB announced the recruitment of Anders Martin-Löf as the new CFO, effective June 1, 2023. Martin-Löf, who has over 20 years of experience in the Life Science sector, previously held roles at companies like Oncopeptides and A3P Biomedical. The current CFO, Jan Mattsson, will transition to a new role as VP Finance after Martin-Löf's arrival. Gunilla Osswald, the CEO, expressed confidence in Martin-Löf's capabilities to aid in the company's development during this exciting phase, particularly in treatments for neurodegenerative diseases. This change comes as BioArctic continues its partnership with Eisai on Alzheimer's therapies.

Positive

• Recruitment of a new CFO with extensive experience in the Life Science sector may bring fresh perspectives.
• Jan Mattsson will remain with the company in a different role, ensuring continuity of leadership.

Negative

• Transitioning CFOs can create temporary instability, potentially affecting strategic continuity.

STOCKHOLM, Feb. 28, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the company has recruited Anders Martin-Löf as its new CFO. Anders Martin-Löf brings broad experience from similar roles at companies such as Oncopeptides, Wilson Therapeutics, RaySearch and most recently at A3P Biomedical. Current CFO Jan Mattsson will remain in his role until Anders Martin-Löf takes up his position and will then move to a newly established role as VP Finance.

"Jan joined BioArctic in early 2017 to assist in the important work of listing the company and has been instrumental to us ever since. I am very pleased that we will keep Jan and his expertise within the company, as he now chooses to step down," says Gunilla Osswald, CEO at BioArctic. "At the same time, I am very pleased that we have succeeded in recruiting Anders Martin-Löf as his successor. BioArctic is in an exciting phase where Anders' knowledge and experience from different parts of the Life Science sector will be of great benefit for our continued development."

"I look forward to becoming part of BioArctic, Sweden's brightest star in biotechnology right now. This is a fantastic opportunity to work with a company that is uniquely positioned to fundamentally change the way patients with severe neurological diseases are treated, says Anders Martin-Löf.

Anders Martin-Löf has Master of Science in Engineering Physics from the Royal Institute of Technology (KTH) in Stockholm and has a Bachelor of Science in Business administration and economics from Stockholm University. He has more than 20 years of experience from the Life Science industry in a number of different roles including CFO, Head of Marketing, Head of Investor Relations as well as several board assignments.

Anders Martin-Löf will join BioArctic on June 1 at the latest, and will be part of the company's group management.

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on February 28, 2023, at 07.15 a.m. CET.

For further information, please contact: 

Oskar Bosson, VP Communications and IR
E-mail:  oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80 

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and ALS. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic's Class B share is listed on Nasdaq Stockholm Large Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

 

The following files are available for download:

https://mb.cision.com/Main/9978/3724630/1879900.pdf

BioArctic hires Anders Martin-Löf as new CFO

 

View original content:https://www.prnewswire.com/news-releases/bioarctic-hires-anders-martin-lof-as-new-cfo-301757498.html

SOURCE BioArctic

FAQ

Who is the new CFO of BioArctic and what is his background?

The new CFO of BioArctic is Anders Martin-Löf, who has over 20 years of experience in the Life Science industry, having held roles at various companies.

When will Anders Martin-Löf officially start his position as CFO at BioArctic?

Anders Martin-Löf will join BioArctic on June 1, 2023, at the latest.

What role will Jan Mattsson take after stepping down as CFO?

Jan Mattsson will transition to a newly established role as VP Finance after Anders Martin-Löf takes over.

What is the significance of this management change for BioArctic?

The management change is significant as it reflects a strategic shift aimed at enhancing BioArctic's capability to advance its treatments for neurodegenerative diseases.